Cited by 765Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentSubstance Abuse Treatment and Outcomes

Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people

Open access
Henquet, Cécile, Krabbendam, Lydia, Spauwen, Janneke, Kaplan, Charles, Lieb, Roselind, Wittchen, Hans-Ulrich, van Os, Jim·2005·BMJ

Abstract

OBJECTIVE: To investigate the relation between cannabis use and psychotic symptoms in individuals with above average predisposition for psychosis who first used cannabis during adolescence. DESIGN: Analysis of prospective data from a population based sample. Assessment of substance use, predisposition for psychosis, and psychotic symptoms was based on standardised personal interviews at baseline and at follow up four years later. PARTICIPANTS: 2437 young people (aged 14 to 24 years) with and without predisposition for psychosis. MAIN OUTCOME MEASURE: Psychotic symptoms at follow up as a function of cannabis use and predisposition for psychosis at baseline. RESULTS: After adjustment for age, sex, socioeconomic status, urbanicity, childhood trauma, predisposition for psychosis at baseline, and use of other drugs, tobacco, and alcohol, cannabis use at baseline increased the cumulative incidence of psychotic symptoms at follow up four years later (adjusted odds ratio 1.67, 95% confidence interval 1.13 to 2.46). The effect of cannabis use was much stronger in those with any predisposition for psychosis at baseline (23.8% adjusted difference in risk, 95% confidence interval 7.9 to 39.7, P = 0.003) than in those without (5.6%, 0.4 to 10.8, P = 0.033). The risk difference in the "predisposition" group was significantly greater than the risk difference in the "no predisposition" group (test for interaction 18.2%, 1.6 to 34.8, P = 0.032). There was a dose-response relation with increasing frequency of cannabis use. Predisposition for psychosis at baseline did not significantly predict cannabis use four years later (adjusted odds ratio 1.42, 95% confidence interval 0.88 to 2.31). CONCLUSION: Cannabis use moderately increases the risk of psychotic symptoms in young people but has a much stronger effect in those with evidence of predisposition for psychosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.38267.664086.63

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The EDSP study found that any cannabis use at baseline was associated with psychotic symptoms 42 months later.

    “The EDSP study found that any cannabis use at baseline was associated with psychotic symptoms 42 months later (19).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Hans-Ulrich Wittchen professor Correspondence to: J van Os j.vanos@sp.unimaas.nl Papers BMJ Online First bmj.com page 5 of 5 on 8 July 2023 at University of Texas Rio Grande Valley. Protected by copyright. http://www.bmj.com/ BMJ: first published as 10.1136/bmj.38267.664086.63 on 1 December 2004. Downloaded from

Cited by

Sorted by citations

Authors
Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H.-U., & van Os, J.
Affiliations
  • Maastricht University (NL)
  • Max Planck Society (DE)
Venue
BMJ
Publisher
BMJ
Published
2004-12-01
Volume
330
Issue
7481
Pages
11
ISSN
  • 1756-1833 (ISSN-L)
  • 0959-8138
OpenAlex
W2146519036
Cited by
765
References
30
Citations by year
2026: 3 · 2025: 9 · 2024: 9 · 2023: 19 · 2022: 17 · 2021: 14 · 2020: 28 · 2019: 20 · 2018: 32 · 2017: 42 · 2016: 32 · 2015: 58 · 2014: 42 · 2013: 39 · 2012: 49
FWCI
25.33
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Max Planck Institute for Plasma Physics (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
  • Qucosa (Saxon State and University Library Dresden) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
  • National Institutes of Health
  • National Institute on Drug Abuse (R01DA016977)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
cannabis use, psychotic symptoms, youth, adolescence, cannabis use disorder, dose-response relationship, interaction effects, substance use, mental health risk
MeSH terms
Adolescent, Adult, Marijuana Abuse, Disease Susceptibility, Female, Follow-Up Studies, Humans, Male, Prospective Studies, Psychoses, Substance-Induced, Risk Factors, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review